Loading news...
Shares of Lexeo Therapeutics, Inc. (NASDAQ: LXEO - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the ten brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and one has assigned a strong buy
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the Company will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026 at 10:00 a.m. ET in Miami, FL.
Lexeo Therapeutics, Inc. (NASDAQ: LXEO - Get Free Report) CEO Richard Nolan Townsend sold 10,173 shares of the company's stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $6.38, for a total transaction of $64,903.74. Following the completion of the sale, the chief executive officer directly owned 392,483
Lexeo Therapeutics, Inc. (NASDAQ: LXEO - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy
Lexeo Therapeutics, Inc. (LXEO) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences in February: Guggenheim Emerging Outlook: Biotech Summit 2026. Fireside chat on Thursday, February 12, 2026 at 12:30 p.m.
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a series of key senior leadership appointments that underscore the company's continued and growing expertise in cardiovascular medicine and late-stage clinical development. The company also provided an update on the strategic partnership announced in June 2025 with Perceptive Xontogeny Venture Funds and venBio Partners to develop therapies for genetic cardiac diseases utilizing a novel non-viral RNA platform.
Lexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Lexeo Therapeutics, Inc. (LXEO) Discusses Preliminary Data From Phase I/II Trial of LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript
LX2020 generally well tolerated across ten participants with no clinically significant complement activation LX2020 transduction, transcription, and increased protein expression observed across participants with dose-dependent response; mean increase in PKP2 protein of 93% in low-dose cohort and 162% in high-dose cohorts Arrhythmia burden stabilized or improved in majority of participants with dose-dependent response in non-sustained ventricular tachycardia and premature ventricular contractions Company to host webcast today at 8:00 AM ET / 5:00 AM PT NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced preliminary data from the HEROIC-PKP2 Phase I/II clinical trial of LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). Across dose cohorts, LX2020 was generally well tolerated and led to robust transduction, increased PKP2 protein expression, and clinically meaningful improvement or stabilization in measures of arrhythmia burden in the majority of participants.
Shares of Lexeo Therapeutics, Inc. (NASDAQ: LXEO - Get Free Report) traded up 9% during mid-day trading on Friday. The company traded as high as $10.22 and last traded at $10.3250. 304,975 shares traded hands during trading, a decline of 65% from the average session volume of 863,517 shares. The stock had previously closed at
NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 44th Annual J.P.
Lexeo Therapeutics, Inc. (LXEO) Clinician Perspectives on Holistic Management of PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced plans to host a virtual event, “A Clinician's Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy,” at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum on Tuesday, December 9th at 3 PM ET. The session will feature a discussion with Dr. Victoria Parikh, M.D.
The consensus price target hints at a 124.3% upside potential for Lexeo Therapeutics, Inc. (LXEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Lexeo Therapeutics, Inc. has surged after FDA alignment on a pivotal trial for LX2006, targeting Friedreich's ataxia cardiomyopathy. LX2006 shows promising efficacy and safety, with significant LVMI reduction and increased frataxin expression, positioning LXEO as a potential best-in-class therapy. LXEO is well-funded into 2028 after recent financings, and analysts remain bullish, forecasting strong revenue growth if LX2006 succeeds.
FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved comparability report between LX2006 HEK and Sf9 manufacturing processes in November 2025, endorsing use of Sf9 final commercial manufacturing process to begin dosing patients in upcoming pivotal study LX2006 interim clinical data show clinically meaningful improvements across cardiac and neurologic measures of Friedreich ataxia, including left ventricular mass index and the modified Friedreich Ataxia Rating Scale Completed enrollment of LX2020 HEROIC-PKP2 Phase I/II trial with ten participants dosed; interim data from low-dose cohort reported and additional clinical data from high-dose cohorts on track for January 2026 $154 million equity financing to support LX2006 registrational activities and further development of cardiac pipeline; in addition to Q3-25 end cash, cash equivalents and investments, expected to fund operations into 2028 NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today provided business updates across its portfolio and reported third quarter 2025 financial results. “We continue to build significant momentum across our cardiac pipeline, and the recent financing strengthens our ability to execute on essential manufacturing and commercial activities for LX2006 as we look towards registrational readiness,” said R.
Ethic Inc. acquired a new position in shares of Lexeo Therapeutics, Inc. (NASDAQ: LXEO) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,726 shares of the company's stock, valued at approximately $44,000. A number of other
The consensus price target hints at a 108.2% upside potential for Lexeo Therapeutics, Inc. (LXEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (“Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced the closing of its previously announced underwritten public offering and concurrent private placement, for total gross proceeds to Lexeo of approximately $153.8 million, before deducting underwriting discounts and commission and other expenses payable by Lexeo in connection with the transaction and including the full exercise of the underwriters' option to purchase additional shares. In the public offering, Lexeo sold 17,968,750 shares of its common stock at $8.00 per share, which includes the full exercise of the underwriters' option to purchase 2,343,750 shares of Lexeo's common stock.